| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 110,20 | 110,42 | 30.06. | |
| 110,38 | 110,64 | 30.06. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 113,68 | 1.240 | |||
| 112,56 | 670 | |||
| 112,00 | 670 | |||
| 111,44 | 670 | |||
| 111,30 | 4 | |||
| 111,26 | 4 | |||
| 111,22 | 16 | |||
| 111,18 | 72 | |||
| 110,84 | 670 | |||
| 110,32 | 824 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/gis.htm [/URL] | ||||
| 111 | 110,18 | |||
| 791 | 110,16 | |||
| 4 | 110,10 | |||
| 670 | 109,66 | |||
| 16 | 109,26 | |||
| 4 | 109,22 | |||
| 4 | 109,18 | |||
| 150 | 108,80 | |||
| 72 | 108,78 | |||
| 670 | 108,64 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.492 | 1,942 | 4.840 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:47 | 110,04 | 2 |
| 17:29:58 | 110,00 | 33 |
| 17:28:43 | 109,80 | 83 |
| 16:31:39 | 109,02 | 20 |
| 16:06:40 | 109,74 | 48 |
| 15:27:48 | 110,58 | 18 |
| 14:30:56 | 110,62 | 1 |
| 13:26:13 | 110,64 | 4 |
| 12:11:50 | 110,82 | 50 |
| 10:09:07 | 110,50 | 22 |
| 10:09:07 | 110,52 | 279 |
| 10:03:06 | 110,06 | 10 |
| 10:03:05 | 110,08 | 57 |
| 10:03:05 | 110,08 | 18 |
| 10:03:05 | 110,06 | 48 |
| 09:04:35 | 109,96 | 11 |
| Tagesumsatz Xetra | -0,32 -0,29 % | 2.961 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05:10 | Novartis, Gilead Sciences und Co. investieren Milliarden - warum jetzt die nächste Generation der Zelltherapie beginnt | Small- & Micro Cap Investment | |||
| Mo | Gilead (GILD) Moves 3.3% Higher: Will This Strength Last? | 5 | Zacks | ||
| So | Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC | 13 | Insider Monkey | ||
| Fr | Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results | 21 | Insider Monkey | ||
| GILEAD SCIENCES Aktie jetzt für 0€ handeln | |||||
| Do | Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer | 28 | Benzinga.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Di | Novo Nordisk Aktie: Jefferies hebt Kursziel, bleibt vorsichtig | 4investors | Vor der Quartalsbilanz von Novo Nordisk am 5. August nehmen zwei Investmentbanken den dänischen Pharmakonzern unter die Lupe. Beide bleiben bei zurückhaltenden Einstufungen, setzen aber unterschiedliche... ► Artikel lesen | |
| Di | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | ACCESS Newswire | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen | |
| Di | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations | GlobeNewswire (Europe) | NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia... ► Artikel lesen | |
| Di | Nxera Receives $10 Mln Milestone Payment From AbbVie | AFX News | TOKYO (dpa-AFX) - Nxera Pharma Co., Ltd. (SOLTF) on Tuesday said it received a $10 million milestone payment from AbbVie (ABBV) after achieving a fourth R&D milestone under their multi-target... ► Artikel lesen | |
| Di | Cosmos Health Inc.: Cosmos Health Authorizes Up to $5 Million Share Repurchase Program | GlobeNewswire (Europe) | CHICAGO, June 30, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its... ► Artikel lesen |